A Phase 1 interventional study of Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg and OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg in Healthy Subjects, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-05-23.
Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the relative bioavailability of varenicline administered intranasally at its highest intended clinical strength compared to varenicline administered orally at its highest oral tablet strength.
This study was a Phase 1, open-label, randomized, 2-way crossover study to evaluate the relative bioavailability of OC-01 (varenicline) Nasal Spray compared to varenicline administered orally as varenicline oral tablet. Approximately 22 healthy volunteer subjects between 18-65 years of age meeting all other study eligibility criteria were randomized (Treatment Period 1) to receive an intranasal dose of 0.12 mg OC-01 (50 µL spray of 0.06 mg into each nostril) or a single 1 mg oral dose of varenicline oral tablet. Both administrations were delivered while subject is in an overnight fasted state. Subjects then returned at least 14 days later (Treatment Period 2) to receive the alternate dose of varenicline that was delivered at Treatment Period 1. Again, this delivery was performed while subject was in an overnight fasted state.
Participants who terminated early during the application period were asked to complete safety assessments (if the participants agree) prior to study exit. Participants who were terminated early from the study were not replaced.
Oyster Point Pharma, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 10 (100%) have results posted.
First submitted before Oyster Point Pharma, Inc. became part of Viatris Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OC-01 0.12 mg was administered intranasally 50 ul into each nostril in a fasted state
Drug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
Varenicline oral tablet 1mg was administered orally in a fasted stated with 200 ml water
Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mg
Cross over bioavailability study
Also known as: varenicline
Cross over bioavailability study
Also known as: varenicline
AUC0-t
Area under the curve from predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
AUC0-inf
AUC0-inf taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Cmax
Cmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Tmax
Tmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Time frame: Blood samples were taken predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
Creatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment
Creatine shift from baseline to 2 hours post treatment. Elevated creatinine may indicate impaired kidney function.
Time frame: Baseline to 2 hours post treatment
| Milestone | Varenicline Oral Tablet 1 mg, Then OC-01 (Varenicline) Nasal 0.12 mg | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg, Then Varenicline Oral Tablet 1 mg |
|---|---|---|
| Started | 11 | 11 |
| Completed | 11 | 10 |
| Not completed | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
Area under the curve from predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
| h*ng/ml | Varenicline Oral Tablet 1 mg | OC-01 (Varenicline) Nasal Spray 0.12 mg |
|---|---|---|
| AUC0-t | 4.49 ± 3.42 | 98.74 ± 25.49 |
AUC0-inf taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
| h*ng/mL | OC-01 (Varenicline) Nasal Spray 0.12 mg | Varenicline Oral Tablet 1 mg |
|---|---|---|
| AUC0-inf | 8.3 ± 4.09 | 102.83 ± 16.82 |
Cmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
| ng/ml | OC-01 (Varenicline) Nasal Spray 0.12 mg | Varenicline Oral Tablet 1 mg |
|---|---|---|
| Cmax | 0.34 ± 0.13 | 4.63 ± 0.93 |
Tmax taken at predose (time 0), 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, and 120 hours post dose.
| h | OC-01 (Varenicline) Nasal Spray 0.12 mg | Varenicline Oral Tablet 1 mg |
|---|---|---|
| Tmax | 2.0 (0.3 to 3.0) | 3 (1 to 6) |
Creatine shift from baseline to 2 hours post treatment. Elevated creatinine may indicate impaired kidney function.
| Participants | Varenicline Oral Tablet 1mg, Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mg | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg, Then Varenicline Oral Tablet 1 mg |
|---|---|---|
| Creatine Shift From Normal at Baseline to Abnormal After 2 Hours Post-treatment | 3 | 3 |
Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit (60 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OC- 01 (Varenicline) Nasal Spray 0.12 mg | 0/21 (0%) | 0/21 (0%) | 13/21 (61.9%) |
| Varenicline Oral Tablet 1 mg | 0/22 (0%) | 0/22 (0%) | 9/22 (40.9%) |
| Event | OC- 01 (Varenicline) Nasal Spray 0.12 mg | Varenicline Oral Tablet 1 mg |
|---|---|---|
| DizzinessNervous system disorders | 1/21 | 8/22 |
| SneezingRespiratory, thoracic and mediastinal disorders | 7/21 | 0/22 |
| coughRespiratory, thoracic and mediastinal disorders | 6/21 | 0/22 |
| nauseaGastrointestinal disorders | 0/21 | 5/22 |
| vomitingGastrointestinal disorders | 0/21 | 4/22 |
| somnolenceNervous system disorders | 1/21 | 3/22 |
| Nasal pruritusRespiratory, thoracic and mediastinal disorders | 1/21 | 0/22 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 1/21 | 0/22 |
| Abdominal pain upperGastrointestinal disorders | 0/21 | 1/22 |
| Dry mouthGastrointestinal disorders | 0/21 | 1/22 |
| Age, Customized(years) | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mg | Varenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mg | Total |
|---|---|---|---|
| age | 39.5 ± 10.6 | 44.5 ± 14.0 | 42.0 ± 12.4 |
| Sex: Female, Male(Participants) | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mg | Varenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mg | Total |
|---|---|---|---|
| Female | 3 | 7 | 10 |
| Male | 8 | 4 | 12 |
| Ethnicity (NIH/OMB)(Participants) | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mg | Varenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 10 | 9 | 19 |
| Not Hispanic or Latino | 1 | 2 | 3 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | OC-01 (Varenicline Solution) Nasal Spray 0.12 mg Then Varenicline Oral Tablet 1 mg | Varenicline Oral Tablet 1 mg Then OC-01 (Varenicline Solution) Nasal Spray 0.12 mg | Total |
|---|---|---|---|
| United States | 11 | 11 | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Nov 2019, 2 months.
Results were first posted in May 2022, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Varenicline